RecruitingPhase 3NCT06723080

Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

Sponsor

Jiangsu vcare pharmaceutical technology co., LTD

Enrollment

480 participants

Start Date

Dec 30, 2024

Study Type

INTERVENTIONAL

Conditions

Moderate-to-severe Atopic Dermatitis

Summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called VC005 Placebo group, a drug called VC005 high dose group, and others for people with moderate-to-severe atopic dermatitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVC005 low dose group

VC005 low dose group repeat administration

DRUGVC005 high dose group

VC005 high dose group repeat administration

DRUGVC005 Placebo group

VC005 Placebo group repeat administration

Locations(1)

Chinese Academy of Medical Sciences Hospital for Skin Diseases

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06723080

Related Trials

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT077114181 location

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT076903711 location

Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis

NCT0693425215 locations

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

NCT0755866814 locations

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

NCT072115421 location